InvestorsHub Logo
Followers 13
Posts 483
Boards Moderated 0
Alias Born 05/21/2009

Re: None

Monday, 01/17/2011 11:15:21 AM

Monday, January 17, 2011 11:15:21 AM

Post# of 105534
So, CBAI is on the donor form for Osiris right? Looks like Osiris is 90 days away from having the worlds first approved stem cell therapy. This should be an exciting year.


Health Canada requests Osiris additional information on stem cell therapy Prochymal

PBR Staff Writer
Published 17 January 2011
Health Canada has requested additional information in support of Osiris Therapeutics’ application for approval of stem cell therapy Prochymal for the treatment of graft vs. host disease (GvHD).


Health Canada has given Osiris 90 days to answer certain questions raised during the review.

Osiris president and CEO Randal Mills said they intend to work with Health Canada to expeditiously provide them the additional information necessary to complete the application and make this important therapy available to patients in need.

Osiris Therapeutics' pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee.

Osiris and Genzyme formed a strategic alliance for the development and commercialization of Prochymal and Chondrogen.

Under the terms of the agreement, Osiris retains commercialization rights to Prochymal and Chondrogen in the US and Canada.

Genzyme holds these rights in all other countries except Japan, where JCR Pharmaceuticals holds rights to Prochymal for the treatment of patients with hematological malignancies.

Last year, Health Canada has granted Prochymal Priority Review.





http://regulatoryaffairs.pharmaceutical-business-review.com/news/health-canada-requests-osiris-additional-information-on-stem-cell-therapy-prochymal-170111#
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.